Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sangamo Therapeutics (SGMO) Shares Issued (2016 - 2025)

Sangamo Therapeutics has reported Shares Issued over the past 16 years, most recently at $21.3 million for Q3 2025.

  • Quarterly results put Shares Issued at $21.3 million for Q3 2025, up 197.17% from a year ago — trailing twelve months through Dec 2025 was $21.5 million (up 7307.93% YoY), and the annual figure for FY2025 was $21.5 million, up 7307.93%.
  • Shares Issued for Q3 2025 was $21.3 million at Sangamo Therapeutics, up from $179000.0 in the prior quarter.
  • Over the last five years, Shares Issued for SGMO hit a ceiling of $22.5 million in Q1 2024 and a floor of -$21.9 million in Q3 2024.
  • Median Shares Issued over the past 5 years was $585000.0 (2021), compared with a mean of $2.7 million.
  • Peak annual rise in Shares Issued hit 12212.16% in 2023, while the deepest fall reached 57043.75% in 2023.
  • Sangamo Therapeutics' Shares Issued stood at $1.1 million in 2021, then crashed by 96.81% to $34000.0 in 2022, then surged by 44329.41% to $15.1 million in 2023, then tumbled by 98.08% to $290000.0 in 2024, then skyrocketed by 7246.21% to $21.3 million in 2025.
  • The last three reported values for Shares Issued were $21.3 million (Q3 2025), $179000.0 (Q2 2025), and $290000.0 (Q4 2024) per Business Quant data.